


9th–10th
December
2016



NIBIT Foundation

Immuno-Oncology
Masterclass

SIENA



FONDAZIONE
NIBIT

Network Italiano per la Bioterapia dei Tumori

www.fondazionenibit.org

AstraZeneca 

Meeting objective

Deliver a scientifically relevant, educational, and interactive peer-to-peer meeting for investigators participating in AstraZeneca Immuno-oncology (IO) clinical studies.

The curriculum will enable investigators to conduct clinical studies more effectively and efficiently, enhance patient recruitment and retention, and improve patient safety by exploring best practices in the recognition and management of immune-mediated adverse events.

The content of the meeting will cover:

- Sharing best practices in the conduct of IO clinical studies by drawing from the expertise available through the Centre of Excellence (CoE)
- Strategies to enhance recruitment into AstraZeneca IO clinical studies by reviewing the latest clinical data in IO (tumor-specific or pan-tumor), including monotherapy and combination therapies
- Optimal treatment of immune-mediated AEs (imAEs) within the multi-disciplinary team (MDT)
- Other topics of interest that will aid in patient recruitment and retention (specified by SC or CoE; e.g. pseudo-progression)

Friday

9

13.00–14.00

Arrival and light lunch

14.00–14.30

Introduction and objectives - *M. Maio*

14.30–15.00

CoE structure

M. Maio

15.00–16.00

Cancer immunotherapy with checkpoint inhibitors: the supporting rationale

M. Maio

16.00–16.30

Overview of immune-mediated AEs

L. Calabrò

16.30–17.00

Coffee break

17.00–17.30

Patient selection and retention

A.M. Di Giacomo

17.30–18.15

Advances in immune checkpoint inhibitors: examining the evidence to date in NSCLC, SCCHN and bladder cancer

R. Danielli

18.15–18.30

Q&A

Saturday

10

08.30–09.15

Case study presentation: imaging

A.M. Di Giacomo

09.15–11.15

Workshop: case study presentations/ discussions

L. Calabrò, R. Danielli, A.M. Di Giacomo

Defining the optimal patient management for TA (clinical and instrumental disease assessment) and imAEs (pneumonitis, diarrhoea/colitis, skin reactions and hepatic, neurological, endocrine toxicities)

11.15–11.45

Coffee break

11.45–12.45

Workshop: the comprehensive take-home message

M. Maio

Educating the local multi-disciplinary team (MDT), patients and carers on what to expect and when to report

12.45–13.15

Summary and Q&A

Faculty

13.15

Meeting close

13.15–14.00

Lunch

14.00

Departures

CHAIR

Michele Maio

Siena

FACULTY

Luana Calabrò

Siena

Riccardo Danielli

Siena

Anna Maria Di Giacomo

Siena

Scientific Secretariat



FONDAZIONE
NIBIT

Network Italiano per la Bioterapia dei Tumori

Location

Hotel Garden

Via Custoza 2
53100 – Siena